Chris Lewis


Roth Capital Analyst Weighs in on EXACT Sciences Corporation (EXAS) Following 2Q Results

Roth Capital analyst Chris Lewis remains neutral on molecular diagnostics company EXACT Sciences Corporation (NASDAQ:EXAS). Following solid second quarter earnings results, but with …

Roth Capital Raises Price Target For EXACT Sciences Corporation (EXAS) Following USPSTF CRC Recommendation

In a research report released Friday, Roth Capital analyst Chris Lewis reiterated a Neutral rating on shares of EXACT Sciences Corporation (NASDAQ:EXAS), while raising the …

Roth Capital Weighs In on EXACT Sciences Corporation (EXAS) Following Leaked JAMA Article

In a research report published Wednesday, Roth Capital analyst Chris Lewis reiterated a Neutral rating on shares of EXACT Sciences Corporation (NASDAQ:EXAS), with …

We See Exact Sciences Corporation (EXAS) Sell-off as Overdone: Roth Capital

In a research report released today, Roth Capital analyst Chris Lewis reiterated a Buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS), while reducing …

Roth Capital Raises Price Target For Exact Sciences Corporation Following Analyst Day

Roth Capital analyst Chris Lewis weighed in today with a few insights on Exact Sciences Corporation  (NASDAQ:EXAS), after the company held its investor & analyst day on June 25. …

Roth Capital Reiterates Buy on Exact Sciences Corporation; Here’s Why

Exact Sciences Corporation (NASDAQ:EXAS) shares are up 9% today after Anthem Blue Cross announced a positive coverage decision for Exact’s Cologuard test. Anthem is the largest …

Roth Capital Cuts Enteromedics Inc. Price Target To Reflect More Conservative Outlook

Roth Capital’s healthcare analyst Chris Lewis weighed in today with a research report on Enteromedics Inc. (NASDAQ:ETRM), reiterating a Buy rating and reducing the price target …

Roth Capital Slashes Nanosphere Price Target In Half Following 4Q14 Results

In a research report sent to investors, Roth Capital analyst Chris Lewis reiterated a Buy rating on Nanosphere (NASDAQ:NSPH), but reduced the price …

Roth Capital Maintains Buy On Enteromedics Ahead Of 4Q14 Results

In a research report issued today, Roth Capital analyst Chris Lewis maintained a Buy rating on EnteroMedics Inc (NASDAQ:ETRM) with a $3 price target, as …

Roth Capital Remains Bullish On Exact Sciences On The Back Of Cologuard Commercial Launch

Roth Capital analyst Chris Lewis came out today with an update on Exact Sciences Corp (NASDAQ:EXAS), as the company is in the stage of commercialization of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts